Beam Therapeutics (BEAM) Change in Accured Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Accured Expenses for 7 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 450.87% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, up 113.32% year-over-year, with the annual reading at $7.7 million for FY2025, 113.32% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $14.3 million at Beam Therapeutics, up from $2.0 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $70.4 million in Q4 2023, with the low at -$24.3 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $3.0 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses skyrocketed 1359.38% in 2021, then plummeted 7225.56% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $41.1 million in 2021, then plummeted by 79.46% to $8.4 million in 2022, then surged by 733.84% to $70.4 million in 2023, then plummeted by 105.79% to -$4.1 million in 2024, then soared by 450.87% to $14.3 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $14.3 million, $2.0 million, and $9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.